Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Morton, L. M. et al. Blood 107, 265–76 (2006).
Mohamed, A. J. et al. Immunol. Rev. 228, 58–73 (2009).
Davis, R. E. et al. Nature 463, 88–92 (2010).
Pan, Z. et al. ChemMedChem 2, 58–61 (2007).
Honigberg, L. A. et al. Proc Natl Acad Sci USA 107, 13075–80 (2010).
Woyach, A. et al. N. Engl. J. Med. 370, 2286–94 (2014).
Furman, R. R. et al. N. Engl. J. Med. 370, 2352–54 (2014).
Byrd, J. C. et al. N. Engl. J. Med. 374, 323–32 (2016).
Sakamoto, K. M. et al. Proc Natl Acad Sci USA 98, 8554–9 (2001).
Lu, J. et al. Chem. Biol. 22, 755–63 (2015).
Winter, G. E. et al. Science 348, 1376–81 (2015).
Chen, J. G. et al. Blood 131, 2047–59 (2018).
Acknowledgements
This work was supported by the National Natural Science Foundation of China (#81573277, 81622042, 81773567), National Major Scientific and Technological Special Project for “Significant New Drugs Development” (#SQ2017ZX095003) and Tsinghua University Initiative Scientific Research Program. This work was also financially supported by the NSFC (No. 81670187) and Beijing Natural Science Foundation (No. 7172047). We thank Prof. Haitao Li and Prof. Qinghua Tao of Tsinghua University for helpful discussions.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Sun, Y., Zhao, X., Ding, N. et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res 28, 779–781 (2018). https://doi.org/10.1038/s41422-018-0055-1
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41422-018-0055-1
This article is cited by
-
Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia
Leukemia (2025)
-
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
Archives of Pharmacal Research (2025)
-
Targeted protein degradation: advances in drug discovery and clinical practice
Signal Transduction and Targeted Therapy (2024)
-
PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases
Cell Discovery (2024)
-
BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression
Oncogene (2024)
